ECOLAB INC. (ECL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.81%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.81% | Share-based compensation / revenue. Period ending 2026-06-30. $135.80M ÷ $16.84B × 100 ≈ 0.81% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 16.84B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 135.80M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.85B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $16.84B | $135.80M | $2.85B | (m) | (m) | 0.81% | (m) | (m) |
| 2026-03-31 | (m) | $16.45B | $134.70M | $2.80B | $310.90M | (m) | 0.82% | 9.02× | Reported |
| 2025-12-31 | $202.00M | $16.08B | $136.60M | $2.74B | $306.20M | 1.26% | 0.85% | 8.94× | Reported |
| 2025-09-30 | (m) | $15.89B | $134.80M | $2.61B | $302.50M | (m) | 0.85% | 8.62× | Reported |
| 2025-06-30 | (m) | $15.72B | $127.80M | $2.89B | $314.40M | (m) | 0.81% | 9.20× | Reported |
| 2025-03-31 | (m) | $15.68B | $130.00M | $2.84B | $318.40M | (m) | 0.83% | 8.92× | Reported |
| 2024-12-31 | $207.00M | $15.74B | $134.80M | $2.80B | $340.30M | 1.32% | 0.86% | 8.24× | Reported |
| 2024-09-30 | (m) | $15.67B | $131.20M | $2.81B | $355.90M | (m) | 0.84% | 7.89× | Reported |
| 2024-06-30 | (m) | $15.63B | $119.30M | $2.33B | $360.80M | (m) | 0.76% | 6.46× | Reported |
| 2024-03-31 | (m) | $15.50B | $110.70M | $2.16B | $363.30M | (m) | 0.71% | 5.94× | Reported |
| 2023-12-31 | $192.00M | $15.32B | $95.10M | $1.99B | $348.90M | 1.25% | 0.62% | 5.71× | Reported |
| 2023-09-30 | (m) | $15.05B | $94.00M | $1.80B | $327.10M | (m) | 0.62% | 5.51× | Reported |
| 2023-06-30 | (m) | $14.76B | $93.70M | $1.72B | $302.50M | (m) | 0.63% | 5.68× | Reported |
| 2023-03-31 | (m) | $14.49B | $91.00M | $1.66B | $277.10M | (m) | 0.63% | 5.99× | Reported |
| 2022-12-31 | $190.00M | $14.19B | $87.80M | $1.56B | $252.10M | 1.34% | 0.62% | 6.20× | Reported |
| 2022-09-30 | (m) | $13.88B | $84.20M | $1.55B | $225.90M | (m) | 0.61% | 6.87× | Reported |
| 2022-06-30 | (m) | $13.53B | $83.40M | $1.53B | $237.50M | (m) | 0.62% | 6.46× | Reported |
| 2022-03-31 | (m) | $13.11B | $86.40M | $1.56B | $231.90M | (m) | 0.66% | 6.71× | Reported |
| 2021-12-31 | $186.00M | $12.73B | $89.50M | $1.60B | $230.60M | 1.46% | 0.70% | 6.93× | Reported |
| 2021-09-30 | (m) | $12.43B | $89.50M | $1.63B | $235.20M | (m) | 0.72% | 6.92× | Reported |
| 2021-06-30 | (m) | $12.13B | $87.30M | $1.57B | $295.90M | (m) | 0.72% | 5.31× | Reported |
| 2021-03-31 | (m) | $11.65B | $86.00M | $1.32B | $306.10M | (m) | 0.74% | 4.30× | Reported |
| 2020-12-31 | $185.00M | $11.79B | $82.10M | $1.40B | $304.80M | 1.57% | 0.70% | 4.58× | Reported |
| 2020-09-30 | (m) | $11.97B | $81.40M | $1.50B | $304.40M | (m) | 0.68% | 4.92× | Reported |
| 2020-06-30 | (m) | $12.17B | $89.40M | $1.64B | $219.20M | (m) | 0.73% | 7.46× | Reported |
| 2020-03-31 | (m) | $14.98B | $88.00M | $2.04B | $211.90M | (m) | 0.59% | 9.65× | Reported |
| 2019-12-31 | $209.00M | $14.91B | $91.10M | $2.01B | $215.30M | 1.40% | 0.61% | 9.35× | Reported |
| 2019-09-30 | (m) | $14.84B | $92.10M | $2.04B | $221.80M | (m) | 0.62% | 9.18× | Reported |
| 2019-06-30 | (m) | $14.77B | $92.10M | $1.96B | $227.00M | (m) | 0.62% | 8.65× | Reported |
| 2019-03-31 | (m) | $14.70B | $92.90M | $1.96B | $232.30M | (m) | 0.63% | 8.44× | Reported |
| 2018-12-31 | $216.00M | $14.67B | $94.40M | $1.95B | $237.20M | 1.47% | 0.64% | 8.21× | Reported |
| 2018-09-30 | (m) | $14.56B | $94.20M | $1.97B | $263.10M | (m) | 0.65% | 7.50× | Reported |
| 2018-06-30 | (m) | $14.37B | $94.80M | $2.02B | $265.50M | (m) | 0.66% | 7.62× | Reported |
| 2018-03-31 | (m) | $14.14B | $93.30M | $1.95B | $269.00M | (m) | 0.66% | 7.24× | Reported |
| 2017-12-31 | $201.00M | $13.84B | $90.50M | $2.02B | $274.60M | 1.45% | 0.65% | 7.36× | Reported |
| 2017-09-30 | (m) | $13.54B | $89.80M | $1.95B | $267.00M | (m) | 0.66% | 7.30× | Reported |
| 2017-06-30 | (m) | $13.36B | $89.60M | $1.94B | $275.30M | (m) | 0.67% | 7.06× | Reported |
| 2017-03-31 | (m) | $13.22B | $87.50M | $1.92B | $283.10M | (m) | 0.66% | 6.77× | Reported |
| 2016-12-31 | $189.00M | $13.15B | $85.70M | $1.92B | $285.40M | 1.44% | 0.65% | 6.71× | Reported |
| 2016-09-30 | (m) | $13.21B | $85.80M | $1.68B | $272.80M | (m) | 0.65% | 6.16× | Reported |
| 2016-06-30 | (m) | $13.27B | $84.70M | $1.52B | $265.40M | (m) | 0.64% | 5.73× | Reported |
| 2016-03-31 | (m) | $13.34B | $82.00M | $1.55B | $257.40M | (m) | 0.61% | 6.00× | Reported |
| 2015-12-31 | $191.00M | $13.55B | $78.20M | $1.56B | $253.70M | 1.41% | 0.58% | 6.15× | Reported |
| 2015-09-30 | (m) | $13.81B | $76.10M | $1.76B | $256.30M | (m) | 0.55% | 6.86× | Reported |
| 2015-06-30 | (m) | $14.06B | $75.50M | $1.92B | $260.80M | (m) | 0.54% | 7.35× | Reported |
| 2015-03-31 | (m) | $14.24B | $73.60M | $1.99B | $265.90M | (m) | 0.52% | 7.49× | Reported |
| 2014-12-31 | $197.00M | $14.28B | $71.10M | $1.96B | $268.00M | 1.38% | 0.50% | 7.29× | Reported |
| 2014-09-30 | (m) | $14.16B | $71.10M | $1.91B | $271.80M | (m) | 0.50% | 7.01× | Reported |
| 2014-06-30 | (m) | $13.95B | $72.60M | $1.81B | $274.90M | (m) | 0.52% | 6.58× | Reported |
| 2014-03-31 | (m) | $13.72B | $71.30M | $1.65B | $275.10M | (m) | 0.52% | 6.00× | Reported |
| 2013-12-31 | $188.00M | $13.25B | $69.60M | $1.56B | $272.80M | 1.42% | 0.53% | 5.72× | Reported |
| 2013-09-30 | (m) | $12.74B | $68.70M | $1.49B | $267.00M | (m) | 0.54% | 5.56× | Reported |
| 2013-06-30 | (m) | $12.28B | $67.20M | $1.41B | $264.60M | (m) | 0.55% | 5.33× | Reported |
| 2013-03-31 | (m) | $11.90B | $66.00M | $1.39B | $261.90M | (m) | 0.55% | 5.29× | Reported |
| 2012-12-31 | $183.00M | $11.84B | $65.80M | $1.29B | $285.60M | 1.55% | 0.56% | 4.51× | Reported |
| 2012-09-30 | (m) | $10.64B | $62.60M | $1.06B | $258.00M | (m) | 0.59% | 4.10× | Reported |
| 2012-06-30 | (m) | $9.35B | $57.20M | $896.10M | $207.10M | (m) | 0.61% | 4.33× | Reported |
| 2012-03-31 | (m) | $8.09B | $49.60M | $767.90M | $155.80M | (m) | 0.61% | 4.93× | Reported |
| 2011-12-31 | $96.00M | $6.80B | $39.90M | $753.80M | $82.10M | 1.41% | 0.59% | 9.18× | Reported |
| 2011-09-30 | (m) | $6.53B | $36.20M | $793.20M | $62.60M | (m) | 0.55% | 12.67× | Reported |
| 2011-06-30 | (m) | $6.35B | $36.00M | $798.70M | $63.00M | (m) | 0.57% | 12.68× | Reported |
| 2011-03-31 | (m) | $6.18B | $36.00M | $804.70M | $64.30M | (m) | 0.58% | 12.51× | Reported |
| 2010-12-31 | $88.00M | $6.09B | $29.20M | $806.80M | $65.60M | 1.45% | 0.48% | 12.30× | Reported |
| 2010-09-30 | (m) | $6.08B | $35.40M | $799.00M | (m) | (m) | 0.58% | (m) | (m) |
| 2010-06-30 | (m) | $6.06B | $36.60M | $776.90M | (m) | (m) | 0.60% | (m) | (m) |
| 2010-03-31 | (m) | $5.98B | $33.80M | $737.60M | (m) | (m) | 0.56% | (m) | (m) |
| 2009-12-31 | (m) | $5.90B | $37.30M | $681.30M | (m) | (m) | 0.63% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $6.14B | $33.60M | $712.80M | (m) | (m) | 0.55% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $5.47B | $37.90M | $669.00M | (m) | (m) | 0.69% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHURCH & DWIGHT CO INC /DE/ (CHD) | United States | $22.622B | 30.81 |
| STEPAN CO (SCL) | United States | $1.451B | -477.05 |
| Longevity Health Holdings, Inc. (XAGE) | United States | $0.006B | -0.09 |
| PROCTER & GAMBLE Co (PG) | United States | $338.763B | 21.26 |